Literature DB >> 16737670

Integrative oncology in North America.

Stephen M Sagar1.   

Abstract

Integrative oncology is an evolving evidence-based specialty that uses complementary therapies in concert with medical treatment to enhance its efficacy, improve symptom control, alleviate patient distress and reduce suffering. In North America the evolution of research into complementary therapies was delayed by the narrow focus of the Flexner Report. A government-funded research agenda and incorporation of complementary therapies into medical school curricula have been driven by early evidence of efficacy and patient demand. Integrative oncology focuses on the role of natural health products (botanicals, vitamins, and minerals), nutrition, acupuncture, meditation and other mind-body approaches, music therapy, touch therapies, fitness therapies, and more. Some natural health products, such as herbs and their constituent phytochemicals, may be biologic response modifiers that could increase cancer control. Current research stretches from the laboratory to health services. Institutions are exploring the effectiveness gap in their clinical services and are determining efficacy of complementary therapies through randomized controlled trials. Eventually, the goal is to establish practice guidelines through determining relative effectiveness and value through cost-utility studies. The aim of integrative oncology should be one medicine, not alternative; it should be patient-focused; it should be evidence-based; and it should provide the best care for cancer cure, prevention, symptom control, and quality of life.

Entities:  

Mesh:

Year:  2006        PMID: 16737670

Source DB:  PubMed          Journal:  J Soc Integr Oncol        ISSN: 1715-894X


  16 in total

Review 1.  Integrative oncology in Indian subcontinent: an overview.

Authors:  Ananthalakshmi Ramamoorthy; Sunitha Janardhanan; Sathiyajeeva Jeevakarunyam; Nadheem Jeddy; Senthil Eagappan
Journal:  J Clin Diagn Res       Date:  2015-03-01

2. 

Authors:  Isabelle Gaboury; Noémie Johnson; Christine Robin; Mireille Luc; Daniel O'Connor; Johane Patenaude; Luce Pélissier-Simard; Marianne Xhignesse
Journal:  Can Fam Physician       Date:  2016-12       Impact factor: 3.275

3.  Integrating Traditional and Allopathic Medicine: An Opportunity to Improve Global Health in Cancer.

Authors:  Edward L Trimble; Preetha Rajaraman
Journal:  J Natl Cancer Inst Monogr       Date:  2017-11-01

Review 4.  Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review.

Authors:  Esther L Davis; Byeongsang Oh; Phyllis N Butow; Barbara A Mullan; Stephen Clarke
Journal:  Oncologist       Date:  2012-08-29

5.  Canadian integrative oncology research priorities: results of a consensus-building process.

Authors:  L C Weeks; D Seely; L G Balneaves; H S Boon; A Leis; D Oneschuk; S M Sagar; M J Verhoef
Journal:  Curr Oncol       Date:  2013-08       Impact factor: 3.677

6.  Complementary and alternative medicine for cancer patients: results of the EPAAC survey on integrative oncology centres in Europe.

Authors:  Elio Rossi; Alessandra Vita; Sonia Baccetti; Mariella Di Stefano; Fabio Voller; Alberto Zanobini
Journal:  Support Care Cancer       Date:  2014-12-04       Impact factor: 3.603

7.  The Peter Brojde lung cancer centre: a model of integrative practice.

Authors:  M Grossman; J Agulnik; G Batist
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

Review 8.  Acupuncture for cancer pain and related symptoms.

Authors:  Weidong Lu; David S Rosenthal
Journal:  Curr Pain Headache Rep       Date:  2013-03

9.  Complementary and alternative medicine: Do physicians believe they can meet the requirements of the Collège des médecins du Québec?

Authors:  Isabelle Gaboury; Noémie Johnson; Christine Robin; Mireille Luc; Daniel O'Connor; Johane Patenaude; Luce Pélissier-Simard; Marianne Xhignesse
Journal:  Can Fam Physician       Date:  2016-12       Impact factor: 3.275

10.  A systematic review of integrative oncology programs.

Authors:  D M Seely; L C Weeks; S Young
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.